Cytokinetics (CYTK) announced the launch of EARTH-HCM, an online, open access, interactive public health education tool developed by Cytokinetics in collaboration with leading academic ...

Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.

Cytokinetics' lead asset, Aficamten, shows promise in treating obstructive hypertrophic cardiomyopathy (oHCM) with significant improvements in exercise capacity and fewer adverse events compared ...